HDACI-induced thrombocytopenia is caused by its unexpected target

Experimental Hematology

Volumn 40, Issue 9, 2012, Pages 695-697

  Kitamura, Toshio ^a   Inoue, Daichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; FIBRINOGEN RECEPTOR; FR 235222; GLYCOPROTEIN IB ALPHA; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE INHIBITOR; PANOBINOSTAT; PROTEIN NAT10; PROTEIN P53; ROMIDEPSIN; TRANSCRIPTION FACTOR GATA 1; TUBULIN; UNCLASSIFIED DRUG; VORINOSTAT;

CELL MATURATION; COLONY FORMING UNIT; CUTANEOUS T CELL LYMPHOMA; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; ENZYME INHIBITION; HISTONE ACETYLATION; HODGKIN DISEASE; HUMAN; LETTER; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MOLECULAR PATHOLOGY; MULTIPLE MYELOMA; NONHUMAN; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS;

ACETYLATION; BLOOD PLATELETS; CELL PROLIFERATION; CELLS, CULTURED; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; MEGAKARYOCYTES; THROMBOCYTOPENIA; THROMBOPOIESIS; TUBULIN;

EID: 84865041189     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2012.07.001     Document Type: Letter

References (19)

1. Yang X.-J., Seto E. Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol Cell 2008, 31:449-461.
2. Batty N., Malouf, Issa J.P. Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett 2009, 280:192-200.
3. Harberland M., Montgomery R.L., Olson E.N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009, 10:32-42.
4. Bishton M.J., Harrison S.J., Martin B.P., et al. Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. Blood 2011, 117:3658-3668.
5. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev 2002, 1:287-299.
6. Glozak M.A., Sengupta N., Zhang X., Seto E. Acetylation and deacetylation of non-histone proteins. Gene 2005, 363:15-23.
7. Gu W., Roeder R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997, 90:595-606.
8. Sueda A., Younes A., Ben-Yeyuda D., et al. Final analysis: phase II study of oral panobinostat in relapsed/refractory Hodgkin lymphoma patients following autologous hematopoietic stem cell transplant. Blood 2010, 116:419a.
9. Matsuoka H., Unami A., Fujimura T., et al. Mechanisms of HDAC infibitor-induced thrombocytopenia. Eur J Pharmacol 2007, 571:88-96.
10. Iancu-Rubin C., Gajzer D., Mosoyan G., et al. Panobinostat (LBH-589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation. Exp Hematol 2012, 40:564-574.
11. Giver C.R., Jaye D.L., Waller E.K., Kaufman J.L., Lonial S. Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes. Leukemia 2011, 25:362-365.
12. Matsuyama A., Shimazu T., Sumida Y., et al. In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J 2002, 21:6820-6831.
13. Tran A.D., Marmo T.P., Salam A.A., et al. HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions. J Cell Sci 2007, 120:1469-1479.
14. Zilberman Y., Ballestrem C., Carramusa L., et al. Regulation of microtubules dynamics by inhibition of the tubulin deacetylase HDAC6. J Cell Sci 2009, 122:3531-3541.
15. Qian D.Z., Kato Y., Shabbeer S., et al. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res 2006, 12:634-642.
16. Catley L., Weisberg E., Kiziltepe T., et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006, 108:3441-3449.
17. Catalano M.G., Pugliese M., Gargantini E., et al. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo. Int J Cancer 2012, 130:694-704.
18. Perdiz D., Mackeh R., Pous C., Baillet A. The ins and outs of tubulin acetylation: more than just a post-translational modification?. Cell Signal 2011, 23:763-771.
19. Shen Q., Zheng X., McNutt M.A., et al. NAT10, a nuclear protein, localizes to the midbody and regulates cytokinesis and acetylation of microtubules. Exp Cell Res 2009, 315:1653-1667.